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Infarction Registry, Augsburg Hospital, Augsburg, GermanyA B S T R A C TBackground: Reliable burden of disease (BOD) estimates are needed
to support decision making in health care. Objectives: The objective
of this study was to introduce an analysis approach based on
individual-level longitudinal survey data that estimates the burden
of diabetes in patients with coronary heart disease in terms of quality-
adjusted life-years (QALYs) lost. Methods: Data from two postal
surveys (2006, N ¼ 1022; 2010–2011, N ¼ 716) of survivors from the
KORA Myocardial Infarction Registry in Southern Germany were
analyzed. Accumulated QALYs were calculated for each participant
over a mean observation time of 4.1 years, considering the non-
informative censoring structure of the follow-up study. Linear regres-
sion models were used to estimate the loss in (quality-unadjusted)
life-years and QALYs between patients with and without diabetes,
and generalized additive models were used to analyze the nonlinear
association with age. The cross-sectional and longitudinal association
with quality of life (QOL) and QOL change and the impact on mortalityee front matter Copyright & 2015, International S
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Results: Diabetes was associated with a reduced QOL at baseline
(cross-sectional: β ¼ –0.069; P o 0.001), but not with a signiﬁcant
longitudinal QOL change. Mortality in patients with diabetes was
increased (hazard ratio ¼ 1.68; P o 0.005). This resulted in a loss of
0.14 life-years (P ¼ 0.003) and 0.37 QALYs (P o 0.001). Results from
generalized additive models indicated that the burden of diabetes is
less pronounced in older subjects. Conclusions: The application of
the proposed approach provides confounder-adjusted BOD estimates
for the studied time horizon and can be used to compare the BOD
across different chronic conditions. Curative efforts are needed to
diminish the substantial diabetes-related QALY gap.
Keywords: burden of disease, coronary heart disease, diabetes,
population-based, QALYs.
Copyright & 2015, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Diabetes and cardiovascular diseases, such as coronary heart
disease (CHD), are major public health problems [1,2]. Particularly,
the coexistence of metabolic and cardiovascular conditions is
frequent and known to have an overproportional impact on health
outcomes [3–5]. Currently, around 10% of the German adult
population has a diagnosis of CHD and around one-third of them
suffer from diabetes mellitus [6,7]. Although the inﬂuence of
diabetes and CHD on quality of life (QOL) or survival is well studied,
there are few studies investigating the impact of these conditionson combined measures of morbidity and mortality [3,4,8]. To
comprehensively quantify the burden of diseases (BODs), measures
such as quality-adjusted (QA) life-years (QALYs) that account for
both the length and the quality of life are needed. The QALY
concept is based on utility theory and welfare economics and was
established to evaluate the cost-effectiveness of health care inter-
ventions over a certain time horizon [8]. It relies on the idea that
each health state has a preference-based utility value attached to it
and that health can be understood as “value-weighted time,” or
more concretely, as the accumulated product of QOL and life years
(LY), the QALYs [9].ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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to quantify the relative impact of a disease on the society’s
health; and, second, to feed decision analytic models to assess
the cost-effectiveness of large-scale interventions outside of
controlled trials. To date, different methodological approaches
have been used to estimate the burden of speciﬁc conditions
quantitatively. Jia et al. [10–12] proposed to combine aggregated
cross-sectional QOL data sources with abridged life table
statistics to estimate the reduction in quality-adjusted life
expectancy (QALE) due to a speciﬁc condition nationwide. Other
researchers estimated the QALYs lost over a certain time horizon
by using the method of quality-adjusted survival, either by
matching longitudinal primary mortality data with aggregated
cross-sectional QOL data [13,14] or by using longitudinal primary
data [15,16].
While model-based long-term predictions might be limited
in precision and validity, the method of quality-adjusted
survival analyses was not speciﬁcally designed to handle
varying follow-up times resulting from varying study start
and termination dates, as is often the case in population-
based follow-up studies. Although methodological extensions
to handle censoring for quality-adjusted survival have been
published and a lot of data from prospective cohort studies are
available, population-based longitudinal data have rarely been
used for comprehensive BOD studies [17]. A method based on
individual-level longitudinal QOL and respective survival times
that considers the censoring structure in population-based
studies and provides reliable BOD estimates can therefore be
expected to be a valuable extension of current methodological
approaches.
The primary objective of this study was to present an
analysis approach that estimates the burden of diabetes in
patients with CHD in terms of QALYs lost on the basis of
individual-level data from a population-based follow-up
study. The study further analyzes the cross-sectional and
longitudinal association with QOL and QOL change and the
impact on mortality to enhance the understanding of the
observed results and suggests an approach regarding how to
consider the potentially nonlinear relationship between age
and BOD.Fig. 1 – Qualitative description of the data and cMethods
Data Sources
Data for this analysis originated from the KORA (Cooperative
Health Research in the Region of Augsburg) Myocardial Infarction
(MI) registry. This population-based registry has been collecting
information on all cases of coronary deaths and acute nonfatal
MI in inhabitants aged 25 to 74 years in the city of Augsburg and
the two surrounding counties in Southern Germany [18,19]. A
total of 2950 patients who were registered with an acute MI
between 1985 and 2004 and were known to be alive (n ¼ 4394)
answered an initial postal survey between August and December
2006 (67% participated). Because of feasibility issues and
prioritization of research questions to be answered, only a subset
(n ¼ 1022) of statutorily insured patients (88% of the German
population is statutorily insured) of the baseline sample was
followed and patients known to be alive by the end of 2010 were
contacted again in a postal “follow-up” survey in 2011. During the
mean observation time of 4.1 years (mean follow-up time until
censoring), 141 participants died and 716 replied to this follow-up
survey (85% participated). A brief overview of the design of this
follow-up study is provided in the upper part of Figure 1. Both the
2006 and 2011 surveys included standardized questions, assess-
ing socioeconomic characteristics, medical history, current med-
ication, lifestyle habits, quality of medical care, and QOL. Medical
and sociodemographic information recorded at the time of the
last MI were available from the MI registry. The study was
granted full ethical approval by the ethics commission of the
Bavarian Medical Association (registration no. 12057).
Measures
Outcomes
QOL was assessed by using the EuroQol ﬁve-dimensional ques-
tionnaire (EQ-5D). The EQ-5D is a multiattribute descriptive
system comprising ﬁve dimensions (mobility, self-care, usual
activities, pain/discomfort, and anxiety/depression), each of
which has three response levels (no problems/some or moderate
problems/extreme problems). The 243 resulting health states canensoring structure of the follow-up study.
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ranging from –0.205 to 1, using a scoring algorithm based on time
trade-off valuations, that has been derived from valuations of the
general German population [20,21]. Validated information on
mortality of participants was obtained by address search and by
contacting the regional registration authorities (until December
2010) before the follow-up survey was rolled out (2011).
In general, QALYs gained by an individual from the start of the
observation time (i.e., baseline date) to the end of the observation
time (i.e. date of censoring for patients who moved away or were
lost to follow-up, or date of death for those who died) can be
described as the area under the QOL curve, which is given by the
EQ-5D trajectory over time [22]. Unlike randomized controlled trials,
population-based studies have no prespeciﬁed study start or end.
Therefore, individual accumulated (QA)LYs depend on the length of
observation times, which may differ individually because of early
or late study enrollment and censoring. As graphically illustrated in
Figure 1, the study start of an individual in our follow-up study is
typically scattered within a range of weeks or months around the
“mean study start,” depending on the sample size and the recruit-
ment capacities. The technical censoring reﬂects the assessment of
the vitality status (national death registries, registration author-
ities) before conducting the follow-up survey, and censoring dates
of survivors (both follow-up participants and nonparticipants)
therefore commonly deviate within a certain range around a mean
censoring date. Only those participants who moved abroad or
cannot be tracked because of other reasons might have signiﬁ-
cantly earlier censoring dates (only two in this study).
As in a classical survival analysis, the difference between the
mean study start and the mean censoring date is referred to as
the mean follow-up time of the study (4.1 years in this study).
Because all censored subjects could be followed until the end of
the study period, it can be assumed that the censoring, whether it
is due to the end of the study or due to nonresponse, is of a
noninformative nature, that is, that the distribution of censoring
dates is independent of personal characteristics or expected
outcomes. The noninformative censoring assumption is sup-
ported by the data of our study. They show that personal
characteristics such as sex, education, smoking, weight status,
diabetes, and myocardial reinfarction lead to small differences in
raw follow-up times, which are in the range of expected random
error (0.01 years). Thus, the raw follow-up times until censoring
or death can be expected to reﬂect the quality-unadjusted survival
in an unbiased manner and can be used for the calculation of
QALYs and subsequently for (QA)LY gap estimations.
Because only one (baseline) or two (baseline and follow-up)
EQ-5D measurements were available in this study, we differ-
entiated between three different cases for the quantiﬁcation of
accumulated QALYs over the follow-up period: 1) an individual is
alive at the date of censoring and participates in the subsequent
follow-up survey (QOL is known at baseline and follow-up); 2) an
individual is alive at the date of censoring but does not partic-
ipate in the follow-up survey (QOL is known only at baseline); and
3) an individual dies within the follow-up period and the date of
death is known (QOL is known only at baseline).Case 1: QOL is known at baseline and follow-up
Although the exact individual trajectory of QOL between the
baseline and follow-up surveys is not known, one can approx-
imate the accumulated QALYs until the date of censoring by
assuming a linear change in QOL values from the baseline survey
to the follow-up survey. For example, a person with a raw follow-
up time of 4.0 years (from baseline survey to censoring), an EQ-5D
value of 0.88 at baseline, and an EQ-5D value of 0.84 at date of
censoring accumulates 4.00 (unadjusted) LYs and 4.0  (0.88 þ
0.84) / 2 ¼ 3.44 QALYs. The QOL value at the date of censoring canbe estimated by the use of linear interpolation using the QOL
values at baseline and follow-up date.
Case 2: QOL is known only at baseline, the person does not
participate in the follow-up survey
To get an approximation for unknown QOL values at the time of
censoring, we imputed missing QOL values using the method of
multiple (n ¼ 10) predicted mean matching given the covariate
and QOL values of the sample at baseline and the QOL values of
the participating subsample at follow-up. This imputation pro-
cedure was based on a missing-at-random assumption. Accumu-
lated QALYs can be calculated analogous to case 1, assuming a
linear change in QOL from baseline to the date of censoring.
Case 3: QOL is known only at baseline, the person dies
Because it is known that the QOL of an individual depends on the
remaining time until death (people close to death commonly
report lower QOL values), we used a pragmatic data-driven
approach to account for this relationship [23]. For this, we ﬁtted
a linear regression model for study participants who died, with
baseline QOL value as dependent variable and “time until death”
as dependent variable. The obtained slope (β estimate) from this
model indicated that for each year a person moves closer to the
date of death, the EQ-5D score declines by 0.035 points (P ¼ 0.13).
We used this estimate of yearly decline in QOL to approximate
the QOL trajectory from baseline to death. For example, a person
with a baseline EQ-5D of 0.60 who died after 2.0 years accumu-
lated 2.0 unadjusted LYs and 2  [0.60 þ (0.60 – 2  0.035)] / 2 ¼
1.13 QALYs. To assess the sensitivity of the assumptions made
for the trajectory of QOL from baseline to death, we examined
two other simple scenarios. First, we assumed an unchanged
course of baseline EQ-5D until death as a conservative approach,
which potentially underestimates the decline in QOL: 2  (0.60 þ
0.60) / 2 ¼ 1.20 QALYs. Second, a linear EQ-5D score change from
baseline to “0” at point of death was examined as a nonconser-
vative approach, which probably overestimates the decline in
QOL: 2  (0.60 þ 0.00) / 2 ¼ 0.60 QALYs.
Predictor variables and covariates
The status of diabetes was based on self-reported information
documented in the baseline questionnaire in 2006. Participants
were asked whether they have diabetes and if so, what kind of
treatment they currently receive (no treatment/diet, oral anti-
diabetic medication only, or insulin therapy/insulin therapy
combined with oral antidiabetic medication). Validated informa-
tion about reoccurrence of cardiac events was obtained from the
core documentation of the MI registry.
Baseline covariates—age (continuous), sex, educational status
(primary education r9 years of school; secondary and tertiary
education49 years of school), smoking status (never smoker, ex-
smoker, current smoker), and weight status (normal weight body
mass index [BMI], o25; overweight, 25 r BMI o 30; obese, BMI Z
30)—were extracted from self-reports of the baseline survey and
from the database of the MI registry.
Statistical Analysis
We ﬁrst analyzed the cross-sectional association between the
predictor variables and baseline EQ-5D scores, using ordinary
least square linear regression models. Analogously, we analyzed
the EQ-5D score changes between baseline and follow-up in the
subsample of patients who also participated in the follow-up
survey to describe the effect of diabetes and reinfarction status
prospectively over time. Cox proportional hazard regression was
applied to estimate the effect of diabetes and reinfarction and
QOL on mortality. To test whether systematic nonresponse has
Table 1 – Characteristics of sample at baseline
(2006) and follow-up participation (2010–2011).
Characteristic Value
Age (y), mean  SD 67.6  9.7
Sex, n (%)
Women 215 (21.0)
Men 807 (79.0)
Education, n (%)
Primary 707 (74.6)
Secondary 241 (25.4)
Weight status, n (%)
Normal 265 (25.9)
Overweight 499 (48.8)
Obese 258 (25.2)
Smoking status, n (%)
Never smoker 327 (32.5)
Ex-smoker 562 (55.8)
Current smoker 118 (11.7)
One or more myocardial reinfarctions, n (%) 121 (11.8)
Diabetes, n (%) 277 (28.0)
Diabetes treatment, n (%)
No treatment/diet 24 (8.8)
Oral medication* 139 (50.9)
Insulin therapy† 110 (40.3)
Diabetes duration (y), mean  SD 10.4  9.5
Time since last MI (y), mean  SD 8.5  5.2
Follow-up participation (2010–2011)
Observation time until censoring (y), mean  SD 4.09  0.1
Alive, follow-up QOL data 716 (70.1)
Alive, no follow-up QOL data 165 (16.1)
Died during follow-up 141 (13.8)
MI, myocardial infarction; QOL, quality of life.
*Oral antidiabetic medication only.
†Insulin therapy or insulin therapy combined with oral antidia-
betic medication.
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responding were regressed on baseline variables in the subsam-
ple of survivors.
To obtain a confounder-adjusted absolute BOD measure, we
analyzed the (QA)LY gap over the 4.1-year time horizon, that is,
the (QA)LY difference between people with and without diabetes
and reinfarction. For this, LYs (raw follow-up times until censor-
ing or death) and QALYs were regressed on the baseline diabetes
and myocardial reinfarction status, by using ordinary least
square regression (OLS) models. As justiﬁed above, the use of
unadjusted LYs and derived QALYs can be expected to lead to
unbiased (QA)LY-gap estimations.
Because it is known from previous studies that, ﬁrst, the
relationship between age and QOL is nonlinear [5] and, second, that
the impact of diabetes on QOL decreases with age [24], a sophisti-
cated analysis and description of the disease burden needs to take
into account these important factors. Previous studies have shown
that generalized additive models (GAMs) are a useful method to
describe and visualize nonlinear relationships in the ﬁeld of out-
comes research [5,25]. Beside the main OLS-based analyses, we
therefore also ﬁtted a GAM with and without a factor-smooth
interaction between age and the predictor variable diabetes. The
model with the factor-smooth interaction can be notated as
Yi¼β0þ½f age, diab agei
  I xdiab¼1ð Þ
þ½f age, diab agei
  I xdiab¼0ð ÞþβdiabxdiabþβxTi þεi
where Yi is the response of the individual i, namely, the accumu-
lated (QA)LYs over the follow-up period; fage is the nonparametric
smooth function of the covariate age; βdiabxdiab is the main effect of
the predictor variable diabetes; xTi β is the linear predictor of other
categorical covariates; and εi are the error terms, which are assumed
to be normally distributed [26]. As in the main (OLS-based) analysis,
a Gaussian distribution and an identity link were used for this
analysis [27]. Likelihood ratio tests were performed to check
whether the introduction of the interaction term signiﬁcantly
improves the model ﬁt, that is, whether the QALY gap remains
constant over age. To check whether the choice of the GAM is
appropriate, we compared the predictive ability of GAMs with that
of OLS-based regression models. For both outcomes, LYs and
QALYs, the predictive ability (adjusted R2) of GAMs was substantially
higher. We further cross-checked the results with an extended (i.e.,
with interaction between a categorical age variable and diabetes)
OLS-based model.
All data analyses, except the GAMs, were performed with the
software package SAS 9.2 (SAS Institute, Cary, NC, USA). The SASMI
and MIANALYZE procedure was used for the calculation of the (QA)
LY gap, to account for the variability in the structure of multiple
imputed data sets. The estimation of the additive model was
carried out with the statistical software R (R Foundation for
Statistical Computing, version 3.1.0, Vienna, Austria) by applying
the mgcv-package. Because of the high computational effort that is
related with the analysis of GAMs based on multiple imputed data
sets, we calculated this model on a single data set. All models were
adjusted for the previously speciﬁed set of covariates.Results
Studied Sample
The characteristics of the cohort are presented in Table 1. The
mean age at baseline was 67.6 years, and the majority of the
patients were men (79%). 12% of the participants suffered from a
reinfarction, and the time since the last MI averaged 8.5 years.
Furthermore, almost one-third of the sample had diabetes, with
9% reporting receiving no speciﬁc treatment, 51% the intake of
oral antidiabetic medication, and 40% the use of insulin.Cross-Sectional and Longitudinal Association between
Diabetes, Reinfarction, and QOL
Effect estimates for cross-sectional and longitudinal associations
with QOL are presented in Table 2. The mean EQ-5D score of the
cohort at baseline was 0.869  0.181. In the cross-sectional
perspective, diabetes (β ¼ –0.069; P o 0.001) and myocardial
reinfarction (β ¼ –0.064; P o 0.001) were associated with reduced
EQ-5D scores. Insulin-dependent patients reported considerably
lower QOL values than did people without diabetes (β ¼ –0.129; P
o 0.001) and patients with diabetes not taking insulin (β ¼ –0.098;
P o 0.001).
The yearly change in QOL over the follow-up period averaged
–0.012  0.041 points. Neither myocardial reinfarction nor dia-
betes and treatment status had a signiﬁcant impact on the QOL
change over the 4.1-year follow-up period.
Association between Diabetes, Reinfarction, QOL, and
Mortality
Hazard ratios (HRs) from the Cox regression models are presented
in Table 3. Although patients who suffered from a myocardial
reinfarction did not have a signiﬁcantly increased mortality risk
(HR ¼ 1.54; P ¼ 0.07), patients with diabetes (HR ¼ 1.68; P ¼ 0.005),
and particularly those taking insulin (HR ¼ 2.25; P o 0.001), were
at a higher risk of dying. QOL was found to be an independent
predictor for mortality. A 0.01-point higher baseline EQ-5D score
reduced the mortality risk by around 2.3% (P o 0.001).
Table 2 – Adjusted effect estimates of linear regression models for the cross-sectional and longitudinal
association between myocardial reinfarction/diabetes and QOL (change) at baseline and over the follow-
up period.
Model Cross-sectional association, EQ-5D score
at baseline (0.869  0.181) (SD)
Longitudinal association, EQ-5D score change
(per year) (–0.012  0.041) (SD)
Adjusted mean
(95% CI)
Difference
(P value)
Adjusted mean
(95% CI)
Difference
(P value)
No reinfarction 0.878 (0.866–0.890) Reference –0.012 (–0.015 to –0.009) Reference
Reinfarction 0.815 (0.782–0.847) –0.064 (o0.001) –0.012 (–0.022 to –0.003) 0.000 (0.999)
No diabetes† 0.890 (0.877–0.903) Reference –0.011 (–0.015 to –0.008) Reference
Diabetes† 0.821 (0.799–0.842) –0.069 (o0.001) –0.015 (–0.022 to –0.009) –0.004 (0.268)
No diabetes† 0.890 (0.877–0.903) Reference –0.011 (–0.015 to –0.008) Reference
Diabetes (no insulin therapy)† 0.859 (0.831–0.887) –0.031 (0.052) –0.013 (–0.021 to –0.005) –0.002 (0.676)
Diabetes (insulin therapy)† 0.761 (0.727–0.794) –0.129 (o0.001) –0.020 (–0.031 to –0.009) –0.009 (0.135)
CI, conﬁdence interval; EQ-5D, EuroQol ﬁve-dimensional questionnaire; QOL, quality of life.
* Model adjusted for age, sex, education, smoking, weight status, and diabetes.
† Model adjusted for age, sex, education, smoking, weight status, and myocardial infarction.
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Results from the logistic regression model showed that most of
the personal baseline characteristics were not predictive for
participation in the follow-up study. Only people with diabetes
(odds ratio ¼ 1.57; 95% conﬁdence interval 1.06–2.33) and those
with lower baseline QOL values (odds ratio ¼ 1.016; 95% con-
ﬁdence interval 1.006–1.026) were more likely to not answer the
follow-up survey.Association between Diabetes, Reinfarction, and Accumulated
(QA)LYs over the Follow-Up Period
The ordinary least square means estimates for accumulated LYs
and QALYs are presented in Table 4. Over a mean observation
time of 4.1 years, the cohort gained on average 3.87 unadjusted
LYs and 3.27 QALYs. Having a history of a myocardial reinfarction
did not signiﬁcantly decrease the accumulated LYs but decreased
the accumulated QALYs by 8% (–0.27 QALYs; P ¼ 0.003). The gapTable 3 – Adjusted hazard ratios (HRs) of Cox
regression models for the association between
myocardial reinfarction, diabetes, EQ-5D scores,
and mortality.
Model HR (95% CI) P value
No reinfarction* 1 Reference
Reinfarction* 1.54 (0.97–2.44) 0.067
No diabetes† 1 Reference
Diabetes† 1.68 (1.17–2.40) 0.005
No diabetes† 1 Reference
Diabetes (no insulin therapy)† 1.33 (0.85–2.10) 0.217
Diabetes (insulin therapy)† 2.25 (1.42–3.56) o0.001
EQ-5D score‡,§ 0.977 (0.970–0.984) o0.0001
CI, conﬁdence interval; EQ-5D, EuroQol ﬁve-dimensional
questionnaire.
* Model adjusted for age, sex, education, smoking, weight status,
and diabetes.
† Model adjusted for age, sex, education, smoking, weight status,
and myocardial infarction.
‡ Model adjusted for age, sex, education, smoking, weight status,
myocardial infarction, and diabetes.
§ HR per 0.01 point increase.between people with and without diabetes averaged 0.14 LYs
(–3.5%; P ¼ 0.003) and –0.37 QALYs (–10.9%; Po 0.001), respectively.
Particularly, patients with diabetes taking insulin accumulated
substantially less QALYs than did those not having diabetes (–0.65;
Po 0.001) and those with diabetes receiving no or oral antidiabetic
medication (–0.35 QALYs; P o 0.001). Taking the conservative
assumption for the trajectory of QOL from baseline until death
yielded almost identical results compared with the data-driven
scenario. Applying the nonconservative approach resulted in
fewer accumulated QALYs (mean 3.15) and an approximately
10% larger relative QALY gap.
Figure 2 displays the estimated (QA)LYs and 95% conﬁdence
interval from the smooth functions f^ age of covariate-adjusted
GAMs in general (Fig. 2A) and in patients with and without
diabetes (Fig. 2B,C). Expected accumulated (QA)Lys declined from
approximately 4 LYs and approximately 3.6 QALYs at the age of
55 years to around approximately 3.2 LYs and approximately 2.3
QALYs at the age of 85 years, respectively. Both accumulated LYs
and QALYs deteriorated in a nonlinear manner over the age
range (P valueso 0.001). The curves in Figure 2C indicate that the
burden from diabetes slightly diminishes with growing age (like-
lihood ratio test, P ¼ 0.015). The smooth functions from the GAM
and the adjusted means from the OLS regression model, includ-
ing an interaction term consisting of diabetes and categorized
age, showed comparable results.Discussion
The use of individual-level QOL and mortality data from
population-based longitudinal studies is a valuable extension of
current methodological approaches that provides confounder-
adjusted BOD estimates. The resulting measure can be under-
stood as the difference in expected QALYs over a certain time
period between patients at different stages of a disease (i.e., an
“average patient”) compared with those without this disease.
This study shows that in patients with CHD, diabetes is associ-
ated with an 11% reduction in QALYs over a time horizon of
approximately 4 years and that this QALY gap seems to diminish
with growing age.
The EQ-5D has been found to be a valid and reliable outcome
measure in the ﬁeld of cardiovascular and metabolic diseases
[28–30]. With regard to contents, this study conﬁrms results of
previous work, showing that diabetes and a history of a reinfarc-
tion in patients with CHD are associated with reduced QOL and
Table 4 – Adjusted means of linear regression for accumulated LYs and QALYs over the 4.1-y follow-up period.
Model LYs, 3.87 (0.02)* QALYs, 3.27 (0.03)*
Adjusted
mean
(95% CI)
Difference
(P value)
%
difference
Adjusted
mean
(95% CI)
Difference
(P value)
%
difference
No reinfarction† 3.89 (3.85–3.93) Reference Reference 3.31 (3.26–3.38) Reference Reference
Reinfarction† 3.81 (3.69–3.93) –0.08 (0.210) –2.1 3.05 (2.88–3.22) –0.27 (0.003) –7.9
No diabetes‡ 3.92 (3.87–3.97) Reference Reference 3.39 (3.32–3.46) Reference Reference
Diabetes‡ 3.78 (3.7–3.86) –0.14 (0.003) –3.6 3.02 (2.91–3.13) –0.37 (o0.001) –10.9
No diabetes‡ 3.92 (3.87–3.97) Reference Reference 3.39 (3.32–3.46) Reference Reference
Diabetes (no insulin therapy)‡ 3.86 (3.75–3.96) –0.06 (0.266) –1.5 3.19 (3.05–3.34) –0.20 (0.015) –5.9
Diabetes (insulin therapy)‡ 3.66 (3.54–3.79) –0.26 (o0.001) –6.6 2.74 (2.57–2.91) –0.65 (o0.001) –19.2
LY, life-year; QALY, quality-adjusted life-year.
* Mean (standard error).
† Adjusted for age, sex, education, smoking, weight status, and diabetes.
‡ Adjusted for age, sex, education, smoking, weight status, and myocardial infarction.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 9 6 9 – 9 7 6974increased mortality risk [3,4,31,32]. As already known from
studies surveying the general population, it could also be shown
that diabetes-related insulin dependency in patients with CHD is
associated with substantially lower QOL values [4,33].
Despite a strong negative cross-sectional association, we did
not ﬁnd a signiﬁcant longitudinal association between diabetes
and QOL. Because nonresponders to the follow-up survey are
assumed to be individuals with bad or declining health status [34]
and because patients with diabetes were substantially overrepre-
sented in this group, it is likely that the true longitudinal
association between diabetes and QOL is underestimated. This
hypothesis is supported by the fact that the only published study
assessing the longitudinal relationship between diabetes and
Euro-QoL scores also reported no (EuroQol-visual analogue scale)55 60 65 70 75 80 85
0
1
2
3
4
Age
LY
s 
ga
in
ed
  /
  Q
A
LY
s 
ga
in
ed
55 60 65
0
1
2
3
4
LY
s 
ga
in
ed
(A) (B)
Fig. 2 – Estimated LYs and QALYs gained over the 4.1-year follow
additive models (GAMs).
(A) Predicted mean values of LYs (dotted gray line; df ¼ 3.5) and
conﬁdence intervals (thin dotted lines); models adjusted for sex
diabetes; estimated effective degrees of freedom: LYs df ¼ 3.5; Q
(B & C) Predicted mean values of LYs and QALYs for people with
95% pointwise conﬁdence intervals (thin solid lines); models ad
reinfarction; estimated effective degrees of freedom: LYs: for tho
QALYs: for those with diabetes df ¼ 3.3; for those without diabe
Because of the small number of younger patients and the relate
restricted to subjects older than 55 years. LY, life-year; QALY, qor quite small effects (EQ-5D) [35]. Selective dropout due to
deteriorating health status and death, as commonly observed in
the context of cohort studies including multimorbid elderly
populations, therefore requires special consideration in longitu-
dinal QOL studies and in approaches to calculate the BODs. The
introduced method partly overcomes this problem and allows a
comprehensive quantiﬁcation of the disease burden over the
studied time horizon. The results show that accumulated QALYs
over a time period of approximately 4 years were considerably
reduced in patients with diabetes (–11%) and speciﬁcally in those
taking insulin (–19%). Because the accumulated QALYs codepend
on QOL, which differs signiﬁcantly (at baseline), the relative gap
in unadjusted LYs is in general smaller than the gap in QALYs.
Although this study indicates that the combined burden of70 75 80 85
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-up period of the smooth functions f^ age ﬁtted by generalized
QALYs (dotted black line; df ¼ 2.5) and 95% pointwise
, education, weight, smoking, myocardial reinfarction, and
ALYs df ¼ 2.5.
(solid black line) and without (solid gray line) diabetes and
justed for sex, education, weight, smoking, and myocardial
se with diabetes df ¼ 3.6; for those without diabetes df ¼ 2.7;
tes df ¼ 2.4.
d uncertainty in estimation caused by outliers, models were
uality-adjusted life-year.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 9 6 9 – 9 7 6 975diabetes, in terms of QALYs lost, seems to slightly diminish with
age, it also illustrates the large general burden of diabetes,
diabetes-related insulin intake, and reoccurring cardiac events
and highlights the great importance of secondary prevention and
intensive treatment.
The proposed method has some distinct advantages com-
pared with model-based QALY-gap estimations. Because of the
use of individual-level longitudinal data from a population-based
cohort study, instead of combining cross-sectional QOL data with
secondary mortality statistics, we were able to adequately adjust
for some underlying confounders that might actually cause
differences in accumulated QALYs. In addition, although long-
term (life-long) models might be more comprehensive in deter-
mining the BOD from a societal perspective [11,12], due to cohort
and period effects and the unpredictability of advances in health
care, these estimations remain rather hypothetical [36]. This view
is supported by the fact that there is no convincing consensus on
the discount rate of QALYs that accrue in later phases of life,
although this issue crucially determines common QALE-gap
estimations [9]. The presented approach is also not susceptible
to bias that might occur from the strong interrelation between
baseline QOL, the disease condition, and mortality, which has
been found in previous studies [23,37]. Because QOL and survival
times are strongly correlated, accumulated QALYs derived
through an aggregated approach 1n
Pi
1 EQ_5Di
 
 1n
Pi
1 LYsi
 
are
not equal to accumulated QALYs derived through an individual-
level approach (1n
Pi
1ðEQ_5Di  LYsiÞ.
In fact, QALY calculations based on aggregated data system-
atically underestimate the true accumulated QALYs and there-
fore can be valid only if the relationship between QOL and
survival times is equal in the two comparison groups. A previous
study showed that not considering the association between QOL
and time to death (survival) in health economic models also leads
to a misspeciﬁcation of health gains (measured in QALYs) of
preventive interventions [23].
Compared with other subject-based or individual-level qual-
ity-adjusted survival approaches, the proposed method is
designed for use in (population-based) follow-up studies with
unequal follow-up times. The suggested approach does not rely
on rather complex modeling techniques for censored data, where
the mean QOL at each follow-up time is multiplied with the
(unadjusted) probability of surviving to that time point [14,15,17].
Instead, it uses the noninformative censoring structure given in
the context of (population-based) follow-up studies and assigns
an LY and QALY value to each individual, which can be modeled
using standard statistical procedures (OLS regression/generalized
mixed models/GAMs). By including covariates and interaction
terms, one can adjust the results of this approach for a broad
variety of comorbidities and one can also model the burden of
multimorbid conditions. The modeling ﬂexibility is therefore
substantially higher than in previously suggested methods and
allows confounder-adjusted BOD comparisons across various
diseases and (chronic) conditions [14,15]. Finally, slightly modi-
ﬁed approaches can be applied in observational cohort studies to
evaluate the impact of interventions on quality-adjusted survival
in case of the nonapplicability of randomized study designs.
In the interpretation of the results of this study some
limitations need to be considered. The nonresponse bias and
exclusion of nonstatutorily insured patients limited the repre-
sentativeness of the results. Furthermore, the self-reported
nature of diabetes and its treatment regimen (nondifferential
bias), as well as residual confounding due to unmeasured
medical conditions, such as the seriousness of the heart disease
or behavioral aspects, could have led to an underestimation or
overestimation of the results.
The described approach also has some methodological limi-
tations. Because of its limited time horizon, it is not suitable forquantifying the burden of a disease in terms of QALYs lost over a
lifetime, which complicates the interpretability of the results and
requires a consensus on the chosen time horizon. Compared with
previous approaches, it does not quantify the burden of a disease
from its onset, but describes the average burden of a disease over
a speciﬁed time horizon on the basis of a population-based
sample of patients at different stages of the disease [11,13,16].
In this study, the average time since onset of diabetes or the last
reinfarction averaged 10.4 and 8.5 years, respectively. Assessing
the “true” burden of diabetes (from its onset) would require the
collection of QOL, mortality, lifestyle, and biomedical data before
and after its onset to accurately address patient heterogeneity
because previous work has shown that QOL deteriorations in
patients with diabetes are mainly attributable to rather time-
invariant factors [38]. In addition, assumptions made on the
unknown QOL trajectory of people who died or who did not
answer the follow-up survey could have biased the QALY-gap
estimations. This is speciﬁcally the case because the nonres-
ponder analysis showed that the “missing-at-random” assump-
tion for the imputation of missing QOL follow-up values might be
partially violated. Because varying assumptions on the QOL
trajectory until death altered the results rather marginally and
because the proportion of nonresponders (15%) was rather small,
the bias produced because of miss-speciﬁed assumptions on the
QOL trajectories, however, can be assumed to be rather small.
When transferring this approach to other data sources, some
important practical issues should be considered. One should
check initially whether follow-up times until censoring are bal-
anced for the factors of interest. If by chance the raw follow-up
time until censoring differs for the factor(s) to be studied, one can
iteratively shorten the follow-up time of persons with the longest
follow-up time (regardless of their characteristics) until the
groups are balanced in terms of their mean follow-up time until
censoring. With this approach, the mean follow-up time is
artiﬁcially shortened and valuable information remains unused;
however, this approach ensures that QALY-gap estimations are
not subject to systematic bias. Furthermore, in case no informa-
tion about the censoring date of a follow-up responder is given (i.
e., the censoring date is the date of survey reply), the mean
censoring date of the cohort should be used for this subject
instead of using the date of survey reply to avoid systematic bias
that could occur from systematic nonresponse. This technique
has been also applied for our data. The applicability of the
proposed approach should be checked carefully for studies with
a high proportion of censored individuals in an early phase of the
follow-up period because in this case the variability of follow-up
times becomes large and uncertainty around QALY-gap estimates
will be high.
Aiming to draw a comprehensive picture for decision makers,
caregivers, and patients, we applied and suggested an approach
on how to analyze the natural nonlinear pattern of expected
accumulated QALYs over the age range. If applying GAMs or
another modeling technique to describe nonlinear patterns, one
should carefully check whether the predictive ability is substan-
tially increased and consider whether the application outweighs
potential disadvantages, such as overﬁtting.Conclusions
Using individual-level longitudinal data of population-based
studies in the context of noninformative censoring provides
confounder-adjusted BOD estimates without the need for com-
plex modeling approaches. Results indicate that the burden of
diabetes in terms of QALYs is substantial, but diminishes with
increasing age. Further methodological advances are needed to
accurately and comprehensively describe the burden of chronic
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 9 6 9 – 9 7 6976conditions, and preventive and curative efforts are needed to
diminish the observed QALY gaps.Acknowledgments
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